Sequential determination of pharmacokinetics (PK) and pharmacodynamics (PD) of mycophenolate mofetil (MMF) in liver transplant (LT) patients.

被引：0
|
作者：
Brunet, M
Martorell, J
Vidal, E
Jimenez, O
Millan, O
Rojo, I
Cirera, I
Rimola, A
机构：
[1] Hosp Clin Barcelona, IDIBAPS, Liver Unit, E-08036 Barcelona, Spain
[2] Hosp Clin Barcelona, IDIBAPS, Dept Toxicol, E-08036 Barcelona, Spain
[3] Hosp Clin Barcelona, IDIBAPS, Dept Immunol, E-08036 Barcelona, Spain
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2004年 / 4卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
1351
引用
收藏
页码：528 / 529
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients are associated with significantly higher clearance
    Militano, O
    Roache, K
    Shaw, LM
    Figurski, M
    Satwani, P
    Ayello, J
    Wolownik, K
    Foley, S
    Hawkes, R
    Del Toro, G
    Bradley, MB
    George, D
    Garvin, J
    Bhatia, M
    Roman, L
    Cairo, MS
    [J]. BLOOD, 2005, 106 (11) : 518A - 518A
  • [22] Cellcept® (mycophenolate mofetil MMF) and methotrexate (MTX):: Safety and pharmacokinetic (PK) interaction study in rheumatoid arthritis patients.
    Yocum, D
    Kremer, J
    Blackburn, W
    Caldwell, J
    Furst, D
    Nunez, M
    Zuzga, J
    Zeig, S
    Gutierrez, M
    Merrill, J
    Dumont, E
    Leishman, B
    [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S83 - S83
  • [23] PHARMACOKINETICS OF ORAL MYCOPHENOLATE MOFETIL (MMF) AND METABOLITES IN RENALLY IMPAIRED PATIENTS
    SHAH, J
    BULLINGHAM, R
    RICE, P
    TSINA, I
    SWAN, S
    HALSTENSON, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 149 - 149
  • [24] Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine
    Lobritto, Steven J.
    Rosenthal, Philip
    Bouw, Rene
    Leung, Mimi
    Snell, Paul
    Mamelok, Richard D.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (11) : 1570 - 1575
  • [25] Variability in Mycophenolate Mofetil (MMF) Pharmacokinetics and Dose Requirements Across Transplant (tx) Types
    Saqr, A.
    Mohamed, M.
    Onyeaghala, G.
    Remmel, R.
    Staley, C.
    Dorr, C.
    Teigen, L.
    Baolin, W.
    Guan, W.
    El-Rifai, R.
    Oetting, W.
    Matas, A.
    Israni, A.
    Jacobson, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1121 - S1121
  • [26] The efficacy and safety of mycophenolate mofetil (MMF) in the treatment of acute and chronic GVHD in bone marrow transplant patients.
    Basara, N
    Blau, W
    Kiehl, MG
    Romer, E
    Rudolphi, M
    Bischoff, M
    Kirsten, D
    Sanchez, H
    Gunzelmann, S
    Fauser, AA
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 : S117 - S117
  • [27] Influence of mycophenolate mofetil and calcineurine inhibitor differences on basiliximab pharmacokinetics in renal transplant patients.
    Haba, T
    Uchida, K
    Katayama, A
    Gotoh, N
    Tominaga, Y
    Matsuoka, O
    Satoh, T
    Uno, N
    Takeda, A
    Morozumi, K
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 183 - 183
  • [28] Enteric-Coated Mycophenolate Sodium (EC-MPS) Has Less GI Side Effects Compared to Mycophenolate Mofetil (MMF) in Liver Transplant Patients.
    de Vera, Michael E.
    Hope, Laurie
    Kikla, Stephenie
    Fedorek, Sheila
    Durant, Stephanie
    Lopez, Roberto
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 533 - 533
  • [29] Benefit of mycophenolate mofetil in immunized renal transplant patients.
    Kliem, V
    vonWoellwarth, J
    Behrend, M
    Schlitt, HJ
    Nashan, B
    Koch, KM
    Pichlmayr, R
    Brunkhorst, R
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3211 - A3211
  • [30] Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporin.
    Lobritto, SJ
    Rosenthal, P
    Bouw, R
    Leung, M
    Snell, P
    Mamelok, R
    [J]. PEDIATRIC TRANSPLANTATION, 2005, 9 : 114 - 115
12345